Wugen

Executive Summary

Wugen is a clinical-stage biotechnology company pioneering off-the-shelf, allogeneic CAR-T cell therapies for oncology and autoimmune diseases. Its lead candidate, WU-CART-007, targets CD7 and is being evaluated in a pivotal trial for T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) and T-cell non-Hodgkin lymphoma (T-NHL), with additional exploration in acute myeloid leukemia (AML) and autoimmune indications. The company recently announced dosing of the first patients in the pivotal study, building on prior Phase 1/2 data that demonstrated a clinically manageable safety profile. Wugen's allogeneic approach offers key advantages over autologous CAR-T therapies, including immediate availability, standardized manufacturing, and potential for broader patient access. With a strong focus on T-cell malignancies and an expanding autoimmune pipeline, Wugen is positioned to address significant unmet needs in hematologic cancers and beyond. The company expects to report pivotal trial data in the coming quarters, which could serve as a major value inflection point.

Upcoming Catalysts (preview)

• H2 2026Pivotal Trial Interim Data for WU-CART-007 in T-ALL/LBL60% success
• Q4 2026Initiation of Autoimmune Indication Study50% success
• TBDPotential Strategic Partnership or Financing40% success